Anticancer slow release preparation of nimustine and its progression agent
A technology of sustained release agent and synergist, applied in the field of anticancer sustained release agent, can solve problems such as unclear effect, and achieve the effects of facilitating drug injection, reducing complications and reducing drug concentration
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0127] Put 70 mg of polylactic acid (PLA) with a molecular weight of 20,000-40,000 as a pharmaceutical excipient into a container, add 100 ml of organic solvent dichloromethane to dissolve and mix well, add 10 mg of nimustine and 20 mg of goserelin, and shake again Then dry in vacuo to remove the organic solvent. Shake again and dry in vacuo to remove the organic solvent. Freezing and pulverizing the dried drug-containing solid composition to make micropowder containing 10% nimustine and 20% goserelin, and then suspending in physiological saline containing 1.5% sodium carboxymethylcellulose to obtain The corresponding suspension-type sustained-release injection has a viscosity of 380cp-460cp (at 25°C-30°C). The subcutaneous release time is 25-30 days.
Embodiment 2
[0129] Put 75 mg of polylactic acid (PLA) with a molecular weight of 30,000-50,000 as a pharmaceutical excipient into a container, add 100 ml of organic solvent dichloromethane to dissolve and mix well, add 10 mg of nimustine and 15 mg of goserelin, and shake again Then dry in vacuo to remove the organic solvent. The dried solid composition is shaped immediately, subpackaged and then sterilized by radiation to obtain an anticancer in vivo implant for treating solid tumors with 10 mg of nimustine and 15 mg of goserelin. The subcutaneous release time is 30-40 days.
Embodiment 3
[0131] Put 80 mg of polylactic acid (PLA) with a molecular weight of 25,000-40,000 as a pharmaceutical excipient into a container, add 100 ml of organic solvent dichloromethane to dissolve and mix well, add 5 mg of nimustine and 15 mg of goserelin, and shake again Then dry in vacuo to remove the organic solvent. The dried solid composition is shaped immediately, subpackaged and then sterilized by radiation to obtain an anticancer in vivo implant containing 5% nimustine and 15% goserelin for treating solid tumors. The subcutaneous release time is 30-40 days.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com